Applied Therapeutics To Be Acquired By Privately Held Cycle Group

Privately held Cycle Group Holdings has agreed to acquire clinical‑stage rare‑disease biotech Applied Therapeutics in a cash tender offer of $0.088 per share, with Applied shareholders also receiving a non‑transferable contingent value right (CVR) worth up to $0.40 per share tied to FDA approvals in galactosemia ($0.10) and CMT‑SORD ($0.10) and $0.20 for achieving $200m in fourth‑quarter net sales, plus a pro rata share of closing cash above $500k (capped at $1.5m). Cycle issued an $8.5m unsecured promissory note to fund Applied’s immediate working capital after the company warned it could not continue operations beyond a limited number of days, and Applied’s board unanimously approved the deal, which is expected to close in Q1 2026 subject to majority tender and customary conditions. The acquisition bolsters Cycle’s rare‑disease portfolio around Govorestat, a CNS‑penetrant aldose reductase inhibitor in development for Classic Galactosemia, CMT‑SORD and PMM2‑CDG, while Applied shares—which have traded between $0.20 and $1.50—fell to $0.21 at close and dropped further to $0.14 in overnight trading following the announcement.

Analysis

Applied Therapeutics agreed to be acquired by privately held Cycle Group Holdings in a cash tender offer of $0.088 per share, with shareholders also receiving a non-transferable contingent value right (CVR) that can deliver up to $0.10 for FDA approval in galactosemia, $0.10 for FDA approval in CMT-SORD, and $0.20 for first achievement of $200m in quarterly net sales, plus a pro rata share of closing cash in excess of $500,000 (capped at $1.5m). The company issued an $8.5 million unsecured promissory note to Cycle to fund near-term working capital after warning it could not continue operations beyond a limited number of days, and Applied’s board unanimously approved the transaction; closing is expected in Q1 2026 subject to a majority tender and customary conditions.

Market reaction was negative: Applied shares, which have traded between $0.20 and $1.50 historically, closed at $0.21 (down 1.41%) on the announcement and fell further to $0.14 in overnight trading (-34.53%), and sentiment metrics are moderately negative, indicating investors view the cash consideration as steeply discounted to recent trading.

Key implications are that the upfront cash offer materially undervalues historical trading levels and places most future upside into a conditional, non-transferable CVR dependent on regulatory approvals and substantial sales milestones; the company’s reported near-term liquidity distress increases pressure on shareholders to tender, while the requirement for a majority tender leaves open execution risk and potential holdout scenarios.

Key Decisions for Investors

• Assess the expected value of the CVR conservatively and compare its present value plus $0.088 to your valuation of the company before tendering, because most upside is milestone-dependent and non-transferable
• Consider tendering only if you require immediate liquidity or if your valuation of the program is lower than the offered cash plus reasonably discounted CVR, given the company’s stated near-term funding shortfall
• Monitor the formal tender offer documents and any SEC filings for minimum tender conditions, termination rights, and details of the $8.5m promissory note, and watch for potential competing bids or revised offers
• If you believe pipeline value materially exceeds the package, consider withholding tender and engaging with management or advisers to explore alternatives, but factor in the operational distress and majority-tender risk